← Eichor
Study identifier: NCT06248554 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Condition: Hepatocellular Carcinoma  ·  Sponsor: Chen Xiaoping

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.

This description comes directly from the study's public registry record.

Talk to the study team

WanGuang D Zhang  ·  +8613886195965  ·  wgzhang@tjh.tjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaWuhan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06248554